Atrial Fibrillation in the Critically Ill Patient

Definition and pathophysiology

Atrial fibrillation (AF) is the most frequent supraventricular arrhythmia in patients with acute coronary syndromes (ACS) and is also a common tachyarrhythmia requiring treatment in decompensated heart failure (DHF). In the critically ill patient, AF may be pre-existing, newly detected for the first time, or newly developed during management of an acute illness.

The clinical relationship between AF and acute deterioration is often bidirectional. AF with a rapid ventricular response may precipitate or aggravate haemodynamic decompensation, whereas acute illness and increased sympathetic drive may promote AF. In DHF, ventricular rate may decrease as dyspnoea improves and sympathetic activation subsides, making it difficult to determine whether AF initiated the deterioration or resulted from it.

AF has important consequences beyond the arrhythmia itself. It may cause symptoms and impaired quality of life, contribute to heart failure, and increase the risk of stroke and other thromboembolic events. Subclinical cerebral injury may contribute to vascular dementia, and thromboembolism may affect organs other than the brain. Patients with AF in the setting of ACS have more comorbidities and a higher risk of complications than patients without AF; both short- and long-term prognosis are worse than in patients who remain in sinus rhythm.

Several mechanisms may account for apparent ischaemic electrocardiographic changes during rapid AF. ST-segment depression or T-wave inversion can occur without coronary artery disease. Proposed explanations in the source material include cardiac memory after abnormal ventricular activation, transient rate-related conduction abnormalities, pacing-related repolarization changes, and inadequate coronary flow relative to myocardial oxygen demand. Consequently, an elevated cardiac troponin concentration and new ST-segment depression in new-onset AF should not automatically be labelled type 2 myocardial infarction without further assessment.

Clinical presentation and symptoms

The clinical presentation is heterogeneous. AF may be well tolerated, particularly when the ventricular response is not excessive, or may cause substantial haemodynamic compromise. Symptoms and consequences may include:

• Palpitations and awareness of an irregular or rapid heartbeat

• Dyspnoea and worsening pulmonary congestion

• Reduced exercise capacity

• Symptoms or signs of heart failure

• Haemodynamic instability

• Myocardial ischaemic symptoms or electrocardiographic changes

• Thromboembolic complications, particularly stroke

In ACS, AF may be present before the acute event, detected for the first time during its management, or arise during the course of treatment. Even transient, self-terminating AF during ST-elevation myocardial infarction may indicate an increased long-term risk of stroke.

In patients with acute decompensated heart failure, AF with rapid ventricular response is particularly important. Cardioversion is generally not immediately indicated if the patient remains significantly decompensated, because recurrence is frequent while the precipitating haemodynamic and sympathetic abnormalities persist. Immediate cardioversion is reserved primarily for instability.

Evaluation and physical examination

Initial assessment should establish whether AF is associated with acute haemodynamic compromise, pulmonary oedema, or evidence of coronary ischaemia. These findings determine the urgency and type of intervention.

The assessment should also clarify:

• Whether AF is pre-existing, newly detected, or newly developed during the acute illness

• The ventricular rate and its relationship to symptoms and haemodynamic status

• Whether heart failure is present and whether left ventricular systolic function is depressed or preserved

• Whether hypotension is present

• Whether an accessory pathway is suspected, particularly before administration of digoxin

• The duration of the AF episode, if known

• The presence of thromboembolic risk factors and the need for anticoagulation

• Potential precipitants and associated comorbidities

Physical examination should focus on perfusion and blood pressure, respiratory status and pulmonary oedema, evidence of heart failure, and clinical manifestations of myocardial ischaemia or systemic embolism. The source material does not provide a detailed, separate physical-examination protocol for critically ill patients.

Diagnostics

Electrocardiography

The diagnosis of AF is established clinically and electrocardiographically, although specific ECG diagnostic criteria are not supplied in the source material. The ECG is essential for documenting the rhythm, assessing the ventricular response, and identifying associated changes.

Rapid AF may produce:

• ST-segment depression

• T-wave inversion

• Rate-related conduction abnormalities

• Repolarization changes resembling ischaemia

These findings should be interpreted alongside symptoms, the timing of symptoms relative to AF onset, serial troponin behaviour, and cardiac imaging or angiographic findings. In the absence of evidence for myocardial ischaemia, an elevated troponin concentration should be considered evidence of myocardial injury rather than automatically classified as myocardial infarction.

Echocardiography

Echocardiographic assessment is relevant to the evaluation of ventricular function and to decisions about rate-control therapy. Depressed left ventricular ejection fraction (LVEF) influences the choice of drugs for ventricular-rate control.

When cardioversion is being considered in an episode lasting more than 48 hours or of unknown duration, transoesophageal echocardiography (TEE) is most commonly used to assess for left atrial appendage thrombus. Cardiac CT angiography with delayed acquisition has also been described as having excellent sensitivity and specificity for this purpose.

Device-based monitoring

Cardiac implantable electronic devices with an atrial lead can reliably detect AF and may provide clinically useful alerts. Remote monitoring can facilitate early recognition of new persistent AF, adjustment of rate- or rhythm-control therapy, and earlier consideration of anticoagulation. In patients with an implantable cardioverter-defibrillator, rapidly conducted AF increases the risk of inappropriate shocks; early identification may permit treatment or device reprogramming.

Device-detected asymptomatic AF episodes as short as 5 minutes have been associated with an increased rate of stroke, although causality is uncertain. Trial evidence cited in the source material describes a reduction in stroke offset by increased bleeding when anticoagulation was used for device-detected episodes lasting 6 minutes to 24 hours.

Biomarkers and laboratory findings

The principal laboratory issue addressed in the source material is cardiac troponin. AF with a rapid ventricular rate may be accompanied by an elevated baseline cardiac troponin concentration and new ST-segment depression, even when coronary artery disease or acute myocardial ischaemia has not been established.

Interpretation requires integration of:

• Ischaemic symptoms

• The temporal relationship between symptoms and AF onset

• Serial changes in cardiac troponin

• Cardiac imaging

• Angiographic findings when indicated

Without evidence of myocardial ischaemia, the troponin elevation should be attributed to myocardial injury. The source material does not provide a broader laboratory evaluation for critically ill patients with AF, including electrolyte, endocrine, inflammatory, or infection-related testing.

Treatment and management

Management is organized around four linked priorities:

• Management of comorbidities and modifiable risk factors

• Prevention of stroke and systemic thromboembolism

• Reduction of symptoms and haemodynamic consequences through rate and rhythm control

• Dynamic reassessment over time

This approach is summarized by the AF-CARE framework: comorbidity and risk-factor management, avoidance of stroke and thromboembolism, reduction of symptoms through rate or rhythm control, and evaluation with ongoing reassessment.

Immediate assessment of instability

Emergent cardioversion is recommended when acute AF is accompanied by significant haemodynamic compromise, pulmonary oedema, or evidence of coronary ischaemia. Synchronized direct-current cardioversion is the preferred approach in this setting. A QRS-synchronous shock is delivered, preferably with sedation when clinically feasible.

In ACS, prompt treatment is required when AF causes haemodynamic instability. Electrical cardioversion is preferred.

Stable patients with new-onset AF

When the patient is haemodynamically stable, the immediate objectives are:

• Control of the ventricular rate

• Assessment and mitigation of thromboembolic risk

• Consideration of restoration and maintenance of sinus rhythm

• Treatment of the associated acute illness and relevant comorbidities

Rate control is particularly important in acute illness because it may prevent further haemodynamic deterioration. Rhythm control may be considered when symptoms persist, rate control is inadequate, or restoration of sinus rhythm is clinically desirable.

Cardioversion and duration of AF

Cardioversion, whether electrical or pharmacological, may precipitate thromboembolism when AF has lasted more than 48 hours or when its duration is unknown. In this setting, either of two approaches is described:

• Initiate uninterrupted anticoagulation and defer cardioversion for at least 3 weeks; or

• Perform imaging to exclude left atrial appendage thrombus, most commonly with TEE, with delayed-acquisition cardiac CT angiography as an alternative described in the source material.

The anticoagulation strategy must also account for long-term thromboembolic risk rather than being limited to the cardioversion episode.

Drugs and practical considerations

Beta-blockers

Beta-blockers can provide rate control, with the choice influenced by the presence of heart failure and reduced LVEF. In patients with systolic dysfunction, cautious beta-blocker use is described as an option. Their use in acute decompensated heart failure requires particular caution because the balance between rate control and further impairment of ventricular function depends on the clinical state.

Digoxin

Digoxin may be used for ventricular-rate control in patients with depressed systolic function. In acute decompensated heart failure, intravenous digoxin is an option when an accessory pathway is absent. In hypotension, digoxin is preferred over amiodarone or beta-blockers. The source material does not provide a dose.

Amiodarone

Amiodarone may be used in patients with depressed LVEF and is generally preferred to digoxin in the ACS guidance when ventricular-rate control is required. It is also an option for AF with rapid ventricular response in systolic dysfunction. In hypotension, however, digoxin is preferred over amiodarone or beta-blockers.

Diltiazem and related agents

Diltiazem and other agents that suppress ventricular function should generally be avoided in patients with significant systolic dysfunction. They may be effective when ventricular function is preserved.

Ibutilide

Intravenous ibutilide is described as a typical pharmacological method for cardioversion in acute AF. It should not be used in patients with a prolonged baseline QT interval or severe left ventricular dysfunction because of the risk of torsades de pointes. The source material does not provide a dose.

For atrial flutter, intravenous ibutilide is recommended for conversion in the absence of QTc prolongation. In-hospital intravenous or oral dofetilide is another recommended option in that setting.

Anticoagulation

Patients with AF and thromboembolic risk factors should receive chronic oral anticoagulation. In ACS, AF of any documented duration is associated with worse outcomes, and anticoagulation should be addressed even when AF is transient or self-terminating if the patient’s risk profile warrants it.

The source material does not provide drug-specific anticoagulant doses or a complete dosing algorithm. It emphasizes that anticoagulation must be considered in relation to both the immediate cardioversion risk and the patient’s longer-term risk of stroke and thromboembolism.

AF in acute coronary syndrome

AF is common in ACS and is associated with more comorbidity and greater complication risk. Most episodes are well tolerated and require no specific antiarrhythmic intervention beyond appropriate anticoagulation, unless the rhythm causes instability.

The management principles are:

• Use synchronized electrical cardioversion promptly when AF causes haemodynamic instability.

• Use beta-blockers for rate control when appropriate, considering heart failure and LVEF.

• Prefer amiodarone or digoxin when LVEF is depressed, with amiodarone generally preferred.

• Prefer digoxin in hypotension.

• Provide chronic oral anticoagulation when thromboembolic risk factors are present.

• Interpret troponin elevation and ST-T abnormalities in clinical context rather than diagnosing myocardial infarction solely from their presence.

AF in acute decompensated heart failure

AF with rapid ventricular response is the most common tachyarrhythmia requiring treatment in DHF. The ventricular rate may fall as dyspnoea and sympathetic activation improve.

Immediate cardioversion is usually avoided in a significantly decompensated but stable patient because recurrent AF is common under these conditions. For patients with systolic dysfunction, the options described are:

• Intravenous digoxin, provided an accessory pathway is absent

• Cautious beta-blocker therapy

• Amiodarone

Diltiazem and other ventricular-function-suppressing agents should generally be avoided in significant systolic dysfunction. They may be used when ventricular function is preserved.

Patients undergoing cardiac resynchronization therapy

AF can compromise effective biventricular pacing through spontaneous, fusion, and pseudo-fusion beats. In persistent or permanent AF, a high proportion of effective biventricular pacing is not achieved in many patients. In those with intact atrioventricular conduction, atrioventricular junction ablation may be required to obtain adequate biventricular capture.

The prevailing expert view supports cardiac resynchronization therapy in patients with permanent AF and New York Heart Association class III or IV heart failure when standard indications are present, provided that atrioventricular junction ablation is added when AF causes incomplete biventricular capture below approximately 90–95%. Holter monitoring may help determine the actual effective capture percentage because device-reported pacing percentages do not always accurately reflect effective biventricular activation.

The source material notes limited evidence in New York Heart Association class II patients and no evidence that QRS morphology or a QRS-duration threshold of 150 ms changes the magnitude of response in permanent AF.

Guideline recommendations

The recommendations applicable to critically ill patients include the following:

Long-term management and follow-up

Acute AF management should not be separated from longer-term care. The AF-CARE framework places management of comorbidities and risk factors at the centre of treatment, followed by stroke prevention, symptom-directed rate or rhythm control, and individualized reassessment.

Follow-up should reassess:

• Recurrence or persistence of AF

• Ventricular-rate control

• Symptoms and functional status

• Heart-failure status and ventricular function

• Anticoagulation indication and bleeding considerations

• The effect of AF on device therapies, including inappropriate ICD shocks or inadequate biventricular pacing

• Whether rhythm-control intervention remains appropriate

• Changes in comorbidities and modifiable risk factors

Remote monitoring through cardiac implantable electronic devices can support earlier identification of persistent AF, adjustment of therapy, and consideration of anticoagulation. Patient education, empowerment, adherence, and shared decision-making are important components of long-term care.

Prognosis

AF in critically ill patients is associated with adverse outcomes, particularly when it occurs in ACS or in the context of heart failure. In ACS, patients with AF have worse short- and long-term prognoses than those in sinus rhythm. AF is also associated with increased risks of stroke, heart failure, other thromboembolic events, and mortality.

The prognosis depends on the underlying acute illness, haemodynamic effect of the arrhythmia, ventricular function, thromboembolic risk, persistence or recurrence of AF, and the success of management of associated comorbidities. Transient AF should not necessarily be regarded as clinically insignificant, because self-terminating AF during STEMI may predict increased long-term stroke risk.

The source material does not provide a single mortality estimate or a dedicated outcome model for AF specifically in the critically ill population.